FUSEN PHARMACEUTICAL

Fusen Pharmaceutical

Company Limited

Fusen Pharmaceutical Co., Ltd. was listed on the main board of the Hong Kong Stock Exchange in 2018, stock code: 1652.hk. Based on the traditional Chinese medicine industry, the company is committed ...

History

Culture

Honors

Shuanghuanglian Oral Liquid 10*10ml

National essential drugs.National medical insurance class A.

Shuanghuanglian Oral Liquid10*20ml

National essential drugs National medical insurance class A Pediatric non-patented drugs listed directly online

Shuanghuanglian Injection

National medical insurance class B National low-cost drugs

Heat-clearing and Detoxicating Oral Liquid

National medical insurance class B

Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2022

2022-03-21 16:50:54

Categories:

Financial reports

File size:

62KB

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2022

2022-03-21 16:50:35

Categories:

Financial reports

File size:

63KB

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2021

2022-01-26 16:21:06

Categories:

Company reports

File size:

63KB

06/28/2022

Two TCM research centers inaugurated in Hengqin Guangdong Macao deep cooperation zone

查看详细 >

06/28/2022

Warmly congratulate Jiaheng pharmaceutical on its approval of the drug production license!

查看详细 >

04/26/2022

Fusen pharmaceutical: metformin hydrochloride sustained release tablets passed the consistency evaluation

Fusen pharmaceutical metformin hydrochloride sustained-release tablets have successfully passed the evaluation of the consistency of quality and efficacy of generic drugs! Metformin Hydrochloride Sustained Release Tablets, a diabetes drug, has been approved by the State Administration for drug control. This product has successfully passed the quality and efficacy consistency evaluation of generic drugs, which is an authoritative recognition of the R & D capacity, production and quality management system and clinical efficacy of Fusen pharmaceutical, further highlights the product brand of Fusen pharmaceutical, helps to improve the market competitiveness of the drug, and accumulates valuable experience for the company's follow-up products to carry out generic drug consistency evaluation. ▲ notice of approval from the State Drug Administration Metformin Hydrochloride Tablets is the basic medicine for diabetes. It is used for diet and physical exercise to control type 2 diabetes patients with blood glucose inefficacy, especially obesity and hyperinsulinemia. As a first-line drug for the treatment of type II diabetes, metformin is often used in combination with other oral hypoglycemic agents. ▲ for medical professionals only Because of the superiority of metformin, it is listed as the first-line treatment for hypoglycemic treatment in the guidelines for prevention and treatment of type II diabetes, formulated by professional academic organizations both at home and abroad. As the holder of drug marketing license, Fusen pharmaceutical will not forget its original intention, forge ahead, strictly control the product quality, and constantly optimize the product layout, so that more drugs of Fusen pharmaceutical can benefit the majority of patients.

查看详细 >

Two TCM research centers inaugurated in Hengqin Guangdong Macao deep cooperation zone

2022

06 .28

Two TCM research centers inaugurated in Hengqin Guangdong Macao deep cooperation zone

Warmly congratulate Jiaheng pharmaceutical on its approval of the drug production license!

2022

06 .28

Warmly congratulate Jiaheng pharmaceutical on its approval of the drug production license!

Fusen pharmaceutical: metformin hydrochloride sustained release tablets passed the consistency evaluation

2022

04 .26

Fusen pharmaceutical: metformin hydrochloride sustained release tablets passed the consistency evaluation

Fusen pharmaceutical metformin hydrochloride sustained-release tablets have successfully passed the evaluation of the consistency of quality and efficacy of generic drugs! Metformin Hydrochloride Sustained Release Tablets, a diabetes drug, has been approved by the State Administration for drug control. This product has successfully passed the quality and efficacy consistency evaluation of generic drugs, which is an authoritative recognition of the R & D capacity, production and quality management system and clinical efficacy of Fusen pharmaceutical, further highlights the product brand of Fusen pharmaceutical, helps to improve the market competitiveness of the drug, and accumulates valuable experience for the company's follow-up products to carry out generic drug consistency evaluation. ▲ notice of approval from the State Drug Administration Metformin Hydrochloride Tablets is the basic medicine for diabetes. It is used for diet and physical exercise to control type 2 diabetes patients with blood glucose inefficacy, especially obesity and hyperinsulinemia. As a first-line drug for the treatment of type II diabetes, metformin is often used in combination with other oral hypoglycemic agents. ▲ for medical professionals only Because of the superiority of metformin, it is listed as the first-line treatment for hypoglycemic treatment in the guidelines for prevention and treatment of type II diabetes, formulated by professional academic organizations both at home and abroad. As the holder of drug marketing license, Fusen pharmaceutical will not forget its original intention, forge ahead, strictly control the product quality, and constantly optimize the product layout, so that more drugs of Fusen pharmaceutical can benefit the majority of patients.

Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station

2022

04 .19

Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station

Recently, the Department of human resources and social security of Guangdong Province issued a notice that the National Postdoctoral Management Committee approved Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of Fusen pharmaceutical, to set up a postdoctoral scientific research workstation branch. ▲ exhibition hall of Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd ▲ exhibition hall of Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. is a research and development subsidiary established by Fusen pharmaceutical in response to the national development strategy of traditional Chinese medicine. In order to enhance the independent research and development ability of traditional Chinese medicine, take the research and development of high-quality and effective traditional Chinese medicine as the main goal, and integrate the high-quality traditional Chinese medicine resources in the industry. ▲ Guangdong Macao science and Technology Industrial Park of traditional Chinese Medicine The company is located in Hengqin Guangdong Macao cooperative traditional Chinese medicine science and Technology Industrial Park. It is the first R & D platform settled in the industrial park and officially operated after the establishment of Hengqin Guangdong Macao deep cooperation zone. It is the supporting unit of the large variety cultivation sub center of traditional Chinese medicine of the national traditional Chinese medicine modernization engineering technology center. Its main business is the R & D of innovative traditional Chinese medicine and secondary development of traditional Chinese medicine, chemical medicine raw materials and preparations, light medicine and beauty products and great health products. This time, Jiaheng pharmaceutical was approved to set up a post doctoral research workstation sub station, which is an affirmation of Jiaheng pharmaceutical's technological innovation ability and R & D ability, creates conditions for the company's talent training and the improvement of technological innovation ability, is conducive to further promoting the company's cooperation with universities and scientific research institutes, is conducive to the introduction of high-end R & D talents, is conducive to further improving the company's independent R & D ability and realizing the landing and transformation of scientific research achievements, Promote the sustainable innovation and development of the company and continuously improve the core competitiveness of the company.

Industrial segment

Fusen Pharmaceutical Company Limited

Chinese patent medicine and chemical generic drugs. The product treatment field covers the fields of respiratory tract, antiviral infection, cardio cerebrovascular, digestion and metabolism, etc.

Weihai Rensheng Pharmaceutical Company Limited

An important part of the layout of the proprietary Chinese medicine segment, the product treatment fields mainly cover dermatology, orthopedics and pediatrics, with a number of exclusive proprietary Chinese medicine approval numbers.

Sales platform

Jiangxi Yongfeng Kangde Pharmaceutical Co., Ltd.

Agency and promotion services of imported drugs

Jiangxi Ruiyuan Pharmaceutical Co., Ltd.

Agency and promotion services of clinical drugs

R & D platform

Beijing Sanye mingming Pharmaceutical Technology Co., Ltd

Nanjing Puji Pharmaceutical Technology Co., Ltd

Fusen (Shenzhen) biomedical R & D Co., Ltd

Fusen (Hengqin) traditional Chinese medicine R & D company

Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd

Jiangsu Puji Pharmaceutical Technology Co., Ltd